ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ALNYLAM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$233.29+1.46 (+0.63%)
Close on Oct 19, 2026
- Market cap
- $32.26B
- P/E (TTM)
- 43.4
- Dividend yield
- –
ALNYLAM PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenues | $1.17B | $1.04B | $994.72M | $851.08M | $672.21M | $468.54M | $450.83M | $420.15M | $410.09M | $365.16M | $346.29M | $313.15M | 90.8% | +74.4% |
| Total TTR | $1.03B | $910.41M | $858.28M | $724.38M | $544.49M | $359.48M | $342.61M | $308.88M | $307.35M | $264.46M | – | – | 79.8% | +89.2% |
| AMVUTTRA | $1.01B | $889.93M | $826.59M | $685.30M | $491.95M | $309.99M | $286.51M | $258.59M | $230.11M | $195.24M | $175.25M | $148.68M | 78.4% | +105.7% |
| Total Rare | $141.89M | $125.72M | $136.44M | $126.70M | $127.72M | $109.06M | $108.22M | $111.26M | $102.74M | $100.71M | – | – | 11.0% | +11.1% |
| GIVLAARI | $89.76M | $74.39M | $86.80M | $73.87M | $80.85M | $66.97M | $64.65M | $71.04M | $62.13M | $58.06M | $59.30M | $54.15M | 7.0% | +11.0% |
| Royalty revenue | $71.67M | $48.97M | $61.37M | $46.20M | $39.98M | $26.47M | $35.39M | $23.39M | $22.40M | $10.62M | $17.02M | $9.91M | 5.6% | +79.3% |
| OXLUMO | $52.12M | $51.32M | $49.65M | $52.83M | $46.87M | $42.09M | $43.57M | $40.22M | $40.61M | $42.65M | $32.73M | $28.74M | 4.0% | +11.2% |
| Collaborations | $47.17M | $82.08M | $40.94M | $351.74M | $61.50M | $99.19M | $106.95M | $57.39M | $227.34M | $118.55M | $76.41M | $427.47M | 3.7% | -23.3% |
| ONPATTRO | $18.46M | $20.48M | $31.69M | $39.08M | $52.54M | $49.49M | $56.10M | $50.29M | $77.24M | $69.22M | $79.01M | $81.59M | 1.4% | -64.9% |
By region
From the segment and revenue-disaggregation notes of Alnylam Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.